Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN NIVEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1336167634
CMS profile
60481
Location
MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$5.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $5.92 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $5.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN NIVEN

NPI 1336167634 · CMS profile ID 60481

Allopathic & Osteopathic Physicians / Dermatology

MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $5.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $5.9210/22/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743814049 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30.02 2
PY2020 $5.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $547,115.16 88
PY2024 Principal investigator $919,823.31 487
PY2023 Recipient $1,200.00 1
PY2023 Principal investigator $635,503.38 419
PY2022 Principal investigator $475,737.00 87
PY2021 Principal investigator $161,162.86 33
PY2020 Principal investigator $161,071.72 49
PY2019 Principal investigator $202,395.85 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $157.00 12/31/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 965540505
Principal investigator 1 ABBVIE INC. $3,209.00 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889825377
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434021
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434023
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434055
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434057
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434059
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434061
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434063
Principal investigator 1 Dermavant Sciences, Inc. $359.12 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434065
Principal investigator 1 Dermavant Sciences, Inc. $1,613.72 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434067
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434069
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434071
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434073
Principal investigator 1 Dermavant Sciences, Inc. $1,514.28 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434075
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434077
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434079
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434081
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434083
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434149
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434151
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434153
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434155
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434157
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434159
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434161
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434163
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434165
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434167
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434169
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434171
Principal investigator 1 Dermavant Sciences, Inc. $1,459.02 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434173
Principal investigator 1 Dermavant Sciences, Inc. $262.44 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435267
Principal investigator 1 Dermavant Sciences, Inc. $262.44 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435269
Principal investigator 1 Dermavant Sciences, Inc. $262.44 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435271
Principal investigator 1 Dermavant Sciences, Inc. $262.44 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435273
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435285
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435287
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435289
Principal investigator 1 Dermavant Sciences, Inc. $1,177.25 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435291
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435293
Principal investigator 1 Dermavant Sciences, Inc. $1,217.03 12/15/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435295
Principal investigator 1 ABBVIE INC. $16,267.00 12/08/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889823981
Principal investigator 1 ABBVIE INC. $3,475.00 11/16/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889820903
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $2,808.18 11/11/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709223
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $164.92 11/09/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709129
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,323.90 11/09/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709139
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,649.20 11/09/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709197
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,319.36 11/09/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709206
Principal investigator 1 ABBVIE INC. $13,022.20 11/08/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889818271
Principal investigator 1 SANOFI US SERVICES INC. $250.00 11/07/2022 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 935664354
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,984.90 11/03/2022 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis No dispute reported 06/30/2026 961874119
Principal investigator 1 ABBVIE INC. $4,680.50 10/13/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889815395
Principal investigator 1 Almirall LLC $1,051.88 10/11/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICALGROUP, LLC
M14867-32 No dispute reported 06/30/2026 902933301
Principal investigator 1 ABBVIE INC. $5,899.30 10/06/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889813133
Principal investigator 1 Almirall LLC $30,499.30 09/12/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICALGROUP, LLC
M14867-32 No dispute reported 06/30/2026 902933247
Principal investigator 1 GENZYME CORPORATION $300.00 09/12/2022 Non-covered Recipient Entity
Lenus Research Medical Group LLC
Activ-POC - AD - Topical No dispute reported 06/30/2026 935598449
Principal investigator 1 ABBVIE INC. $9,444.25 09/08/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889810803
Principal investigator 1 ABBVIE INC. $3,799.00 09/08/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889810805
Principal investigator 1 ABBVIE INC. $20,025.40 08/31/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889808017
Principal investigator 1 ABBVIE INC. $1,737.50 08/16/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889806279
Principal investigator 1 Almirall LLC $16,396.88 08/09/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICALGROUP, LLC
M14867-32 No dispute reported 06/30/2026 902933163
Principal investigator 1 Almirall LLC $2,100.00 08/09/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICALGROUP, LLC
M14867-32 No dispute reported 06/30/2026 902933165
Principal investigator 1 GENZYME CORPORATION $36,700.00 08/08/2022 Non-covered Recipient Entity
Lenus Research Medical Group LLC
Activ-POC - AD - Topical No dispute reported 06/30/2026 935598323
Principal investigator 1 SANOFI US SERVICES INC. $250.00 08/08/2022 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 935663876
Principal investigator 1 ABBVIE INC. $4,813.50 07/14/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889800881
Principal investigator 1 ABBVIE INC. $15,267.35 07/14/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889800883
Principal investigator 1 Almirall LLC $6,443.00 06/30/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICALGROUP, LLC
M14867-32 No dispute reported 06/30/2026 902933105
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,452.84 06/24/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936708741
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,649.20 06/17/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936708835
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,154.44 06/17/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936708845
Principal investigator 1 ABBVIE INC. $4,414.50 06/16/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889795547
Principal investigator 1 ABBVIE INC. $5,160.90 06/16/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis No dispute reported 06/30/2026 889796103
Principal investigator 1 GENZYME CORPORATION $140,600.00 06/02/2022 Non-covered Recipient Entity
Lenus Research Medical Group LLC
Activ-POC - AD - Topical No dispute reported 06/30/2026 935598225
Principal investigator 1 ABBVIE INC. $1,471.50 05/12/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889791119
Principal investigator 1 SANOFI US SERVICES INC. $250.00 05/03/2022 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 935663174
Principal investigator 1 ABBVIE INC. $3,999.00 04/14/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889785871
Principal investigator 1 GENZYME CORPORATION $11,600.00 04/11/2022 Non-covered Recipient Entity
Lenus Research Medical Group LLC
Activ-POC - AD - Topical No dispute reported 06/30/2026 935598145
Principal investigator 1 GENZYME CORPORATION $1,600.00 03/28/2022 Non-covered Recipient Entity
Lenus Research Medical Group LLC
Activ-POC - AD - Topical No dispute reported 06/30/2026 935598113
Principal investigator 1 ABBVIE INC. $13,996.00 03/17/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889782027
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,644.66 03/16/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936708721
Principal investigator 1 SANOFI US SERVICES INC. $750.00 03/14/2022 Non-covered Recipient Entity
Interspond LLC
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 935663277
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $7,552.08 02/23/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936708713
Principal investigator 1 ABBVIE INC. $6,675.50 02/16/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint) No dispute reported 06/30/2026 889777437
Principal investigator 1 GENZYME CORPORATION $11,100.00 02/07/2022 Non-covered Recipient Entity
Lenus Research Medical Group LLC
Activ-POC - AD - Topical No dispute reported 06/30/2026 935598065
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,811.32 01/17/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936708701
Principal investigator 1 ABBVIE INC. $5,212.50 01/12/2022 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP LLC
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint) No dispute reported 06/30/2026 889773355